A randomized prospective clinical trial of the Taylor patch  by Wright, J.Gordon
LETTERS TO THE EDITORS 
The Editors invite readers to submit letters commenting on the contents of articles 
that appear in the JOURNAL. Also welcome are brief communications in letter form 
reporting investigative or clinical observations without extensive documentation 
and with brief bibliography (five titles or less), not requiring peer review but open 
to critique by readers. Letters to the Editors should be no more than 500 words 
in length and they may have to be edited for publication. 
Regarding "Surgical management of infrainguinal 
arterial prosthetic graft infections" 
To the Editors: 
The article by Mertens et al., "Surgical management of
inftainguinal arterial prosthetic graft infections: review of 
a thirty-five year experience" (J VASC SURG 1995;21:782- 
91) does not fairly address the issue of selective complete 
graft preservation for treatment of infected extracavitary 
arterial grafts. We have previously emphasized that com- 
plete graft preservation should only be attempted when the 
graft is patent, the anastomosis i  intact, and the patient is 
not systemically septic. 1 If any of these criteria are not 
fulfilled, graft excision must be performed. 
I would like to mention several points. First, only 
cursory mention was made of the methods used to achieve 
graft preservation; frequency and degree of wound de- 
bridement were not discussed. Second, we have suggested 
that oversewing a 2- to 3-ram remnant of an occluded graft 
on an underlying artery may be acceptable, but it is unclear 
whether large segments of thrornbosed grafts in Mertens' 
series were left in place. Third, the authors state that 
remnants of grafts left in place were "presumably unin- 
fected," which highlights the problems of a retrospective 
study. Obviously these remnants may have been already 
infected, and may have accounted in part for the dismal 
results of graft preservation i this series. Fourth, 13 grafts 
were treated by "local care" despite the fact that four 
patients were septic, four grafts were occluded, two 
patients had hemorrhage, and one presented with an 
infected pseudoaneurysm. Sepsis, graft occlusion, and a 
disrupted anastomosis are contraindications of complete 
graft preservation. Fifth, the amputation rate in Mertens' 
series of patients treated by total graft excision was 30% (12 
of 40); most occurred during the first year after onset of 
graft infection. Although our series included only hospital 
amputation rates, 1we reported markedly improved ampu- 
tation rates of 13% for all infected peripheral grafts and 
only 4% for surviving patients who fulfilled criteria for 
attempted complete graft preservation and who were 
treated with this method. 
I caution that the Cleveland Clinic results of treating 
infected infrainguinal arterial prosthetic graft infections 
may leave readers with an unfair and unjustified assessment 
of selective graft preservation. 
Keith D. Calligaro, ~_D 
Section on Vascular Surgery 
Pennsylvania Hospital 
800 Spruce St. 
Philadelphia, PA 19107-6192 
376 
REFERENCE 
1. Calligaro KD, Veith FJ, Schwartz ML, et al. Selective 
preservation of infected prosthetic arterial grafts: analysis of a 




To the Editors: 
Dr. Calligaro has pointed out some of the flaws of a 
retrospective r view, which of course cannot completely 
resolve all the issues associated with the management of
infrainguinal prosthetic graft infection. Nevertheless, in 
our experience incomplete graft excision for established 
infrainguinal arterial prosthetic graft infection is often, but 
not always, unsuccessful. We have acknowledged that 
factors uch as the advanced stages of graft infection among 
our patients at the time of treatment and the practical 
difficulty in making the diagnosis of a limited graft 
infection suitable for conservative treatment probably have 
influenced our disappointing results with incomplete graft 
excision. 
Our report is not intended to be a plea for routine total 
graft excision to treat all infected infrainguinal arterial 
prosthetic grafts. The intent is, however, to sound a 
cautionary note regarding incomplete graft excision. We 
maintain that patients hould be selected carefully for this 
treatment and observed closely for recurrence whenever it 
is used. 
Patrick J. O'Hara, MJ) 
Department ofVascular Surgery 
Cleveland Clinic Foundation 
9500 Euclid Avenue 
Cleveland, Ohio 44195 
24/41/68305 
A randomized prospective clinical trial of  the 
Taylor patch 
To the Editors: 
We agree wholeheartedly with the comments of Dr. 
Ligush, 1 who recently enjoined the vascular surgery com- 
munity to actively participate in controlled, randomized, 
prospective clinical trials to test the efficacy the Taylor 
patch. 2We also agree with the editorial remarks of John M. 
Porter, MD, who, when referring to Taylor's results, 2 
stated that "if these results can be duplicated in prospective, 
randomized trials, it will represent the single most impor- 
tant improvement in infrainguinal reconstructions since 
their inception. "3 In fact, we agree so strongly with the 
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comments of these two individuals that we initiated such a 
trial approximately 2 years ago. 
The Columbus Vascular Surgery Society Taylor Patch 
Study is a randomized, prospective clinical trial that was 
designed to test the efficacy of the Taylor patch. The 
participating surgeons are all members of the Columbus 
Vascular Surgery Society or the Cleveland Vascular Soci- 
ety. The participating surgeons are not reimbursed for their 
participation i this study. They are volunteering their time 
and skills in a truly altruistic manner in the pursuit of 
scientific truth, and they hope that their efforts will advance 
the field of clinical surgery and will benefit future genera- 
tions of patients and physicians. 
The primary objective of the study is to compare the 
5-year primary patency rate of infrainguinal polytetrafluo- 
roethylene grafts when used with or without a Taylor patch 
for patients with grade 1 (or worse) chronic limb ischemia 
as defined by the SVS/ISCVS. 4 The study is designed to 
accomplish several other objectives as well. To accomplish 
these objectives, patients will be observed at 30 days and at 
3, 6, 12, 24, 36, 48, and 60 months. At each follow-up 
visit, the participating surgeon will record the graft patency 
as defined by the SVS/ISCVS committee for reporting 
standards. 4 In addition, the participating surgeon will 
record if any interval events have occurred and will record 
the grade of chronic arterial insufficiency a and the patient's 
ambulatory status. 
We estimate that we will need 75 patients at each level 
of the distal anastomosis (225 patients in total). The first 
patient was randomized on May 27, 1994, and to date we 
have enrolled more than 70 patients. Our follow-up data is 
92% complete, but because of the relatively few number of 
patients who have had even 12 months of follow-up, it is 
inappropriate atthis time to comment on our early results. 
However, Dr. Ligush and others should rest assured that 
we will continue our efforts to use a randomized, prospec- 
tive clinical trial to test the hypothesis that the Taylor patch 
improves patency rates, and we encourage others to do the 
same. 
j. Gordon Wright, M_D 
On behalf of the participating surgeons in the Columbus Vas- 
cular Surgery Society Taylor Patch Trial 
Division of Vascular Surgery 
Ohio State University 
410 West Tenth Avenue 
Columbus, OH 43210 
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24/41/68525 
Cardiac enzymes in the blood salvaged uring 
abdominal aortic surgery 
To the Editors: 
Elevations in the levels of the enzymes used to diagnose 
myocardial infarction, that is, creatine kinase (CK), its 
isoenzyme CKMB, and lactate dehydrogenase (LDH), are 
known to occur after surgery in the absence of myocardial 
injury. These elevations are caused by trauma during 
surgery to tissues uch as muscle and red blood cells and 
make the diagnosis of myocardial infarction in the imme- 
diate postoperative p riod difficult.1 Additional diagnostic 
criteria, such as CKMB/total CK ratio and LDH1/LDH2 
isoenzymes ratio have been described to differentiate an 
increase in enzyme levels of cardiac origin from that of 
noncardiac origin in the postoperative p riod.l-3 
Intraoperative blood salvage and reinfusion after pro- 
cessing (centrifugation/washing) is widely used during 
abdominal aortic surgery to minimize donor blood use. 
The release of enzymes in the surgical field from trauma- 
tized tissues and the hemolysis caused by suction suggest 
that the salvaged blood may contain large amounts of CK, 
CKMB, and LDH. The reinfusion of this blood, by further 
increasing CKMB or total CK, or by changing LDH 
isoenzyme pattern, may invalidate the criteria used to 
diagnose myocardial infarction in the postoperative p riod. 
The purpose of this study was to determine whether the 
blood salvaged uring abdominal aortic surgery contains 
CK, CKMB, and LDH in amounts large enough to 
complicate the diagnosis of postoperative myocardial 
infarction. 
The study (IRB-approved) was performed on blood 
salvaged uring 13 elective procedures (10 aneurysms, 3 
aortoiliac occlusive disease). The patients (10 men and 
three women; average age, 66 years; range, 46 to 78) had 
normal preoperative CK and LDH levels and no history of 
neuromuscular disorders known to be associated with 
abnormally increased CK or LDH contents in the skeletal 
muscle. Surgery was performed with a midline transab- 
dominal approach with medial visceral rotation. Before 
aortic crossclamping, systemic heparin was administered 
intravenously in a dose of 75 U/kg. The aorta was repaired 
with a straight graft in nine instances and a bifurcated one 
in four. The blood was suctioned from the operative field 
with a standard assembly consisting of a Yankauer suction 
tip, 3.5 m of tubing (internal diameter 6 mm), and a 
cardiotomy reservoir. The negative pressure applied to the 
suction was usually 150 mm Hg and was increased up to 
300 mm Hg during periods of brisk bleeding. Citrate 
(ACD solution A, USP) was added to the aspirated blood 
in approximately a 1:7 ratio to prevent clotting. The 
salvaged blood was processed with a Cell Saver Plus 3 
device (Haemonetics Inc., Braintree, Mass.), operated in 
the standard protocol as preset by the manufacturer. Only 
the first unit of processed blood obtained in each operation 
was included in the study. From each unit a blood sample 
was taken for the following measurements: hematocrit 
(Hct); CK and LDH activity (U/L), with a Hitachi 747 
analyzer and commercially available reagents (Boeringher 
Mannheim Corp., Indianapolis, Ind.); CKMB (~tg/L) with 
an automated immunoassay (Abbott Laboratories, Abbott 
